MSH2 is required for DNA mismatch repair recognition in eukaryotes. Deleterious mutations in human MSH2 account for approximately half of the alleles associated with a common hereditary cancer syndrome. Previously, we characterized clinically identified MSH2 missense mutations, using yeast as a model system, and found that the most common cause of defective DNA mismatch repair was low levels of the variant Msh2 proteins. Here, we show that increased protein turnover is responsible for the reduced cellular levels. Increasing gene dosage of more than half of the missense alleles fully restored function. A titration experiment revealed that raising the expression level of one variant to less than wildtype levels restored mismatch repair, suggesting that overexpression is not always required to regain function. We found that the ubiquitin-mediated proteasome degradation pathway is the major mechanism for increased turnover of the Msh2 variants and identified the primary ubiquitin ligase as San1. Deletion of San1 restored protein levels for all but one variant, but did not elevate wild-type Msh2 levels. The unstable variants interacted with San1, whereas wild-type Msh2 did not. Additionally, san1Δ suppressed the mismatch repair defect of unstable variants. Of medical significance, the clinically approved drug Bortezomib partially restored protein levels and mismatch repair function for low-level variants and reversed the resistance to cisplatin, a common chemotherapeutic. Our results provide the foundation for an innovative therapeutic regime for certain mismatch-repair-defective cancers that are refractory to conventional chemotherapies.
MSH2 is required for DNA mismatch repair recognition in eukaryotes. Deleterious mutations in human MSH2 account for approximately half of the alleles associated with a common hereditary cancer syndrome. Previously, we characterized clinically identified MSH2 missense mutations, using yeast as a model system, and found that the most common cause of defective DNA mismatch repair was low levels of the variant Msh2 proteins. Here, we show that increased protein turnover is responsible for the reduced cellular levels. Increasing gene dosage of more than half of the missense alleles fully restored function. A titration experiment revealed that raising the expression level of one variant to less than wildtype levels restored mismatch repair, suggesting that overexpression is not always required to regain function. We found that the ubiquitin-mediated proteasome degradation pathway is the major mechanism for increased turnover of the Msh2 variants and identified the primary ubiquitin ligase as San1. Deletion of San1 restored protein levels for all but one variant, but did not elevate wild-type Msh2 levels. The unstable variants interacted with San1, whereas wild-type Msh2 did not. Additionally, san1Δ suppressed the mismatch repair defect of unstable variants. Of medical significance, the clinically approved drug Bortezomib partially restored protein levels and mismatch repair function for low-level variants and reversed the resistance to cisplatin, a common chemotherapeutic. Our results provide the foundation for an innovative therapeutic regime for certain mismatch-repair-defective cancers that are refractory to conventional chemotherapies.
Lynch syndrome | MutS | mutator | hereditary nonpolyposis clorectal cancer L ynch syndrome, also known as hereditary nonpolyposis colorectal cancer, is a leading cause of inherited cancer mortality in the United States (1) . Approximately 2-7% of colorectal cancer cases are the consequence of Lynch syndrome, a dominant and highly penetrant disease afflicting individuals at an early age (1) . Although colorectal is the most common form of cancer found in Lynch syndrome families, endometrial, ovarian, stomach, small intestine, liver, gallbladder ducts, upper urinary tract, brain, skin, and prostate cancers are all associated with the syndrome.
Lynch syndrome cancers, as well as many sporadic tumors, are a consequence of defects in mismatch repair; for example, ∼17% of all colorectal cancers originate from defects in mismatch repair (2) . DNA mismatch repair is a conserved mechanism that significantly contributes to the accurate preservation of genetic material (3) . Mismatch recognition is accomplished in eukaryotes by MutS heterodimers in which Msh2 is the invariant partner (4) . Mismatch binding initiates subsequent events, including cleavage and excision of the error-containing strand followed by new synthesis and ligation (5) . Without mismatch repair, DNA displays microsatellite instability and acquires numerous mutations, some of which are deleterious. Included among the types of harmful mutations are ones that lead to cancer in higher organisms. Of clinical significance, mismatch-repair-defective tumors are associated with increased resistance to certain conventional chemotherapies such as 5-fluoruracil (6), cisplatin (7) , and carboplatin (8) .
In the current era of personalized medicine, our research aims to uncover the molecular defects of clinically significant variants of mismatch repair proteins to propose unique approaches to treating tumors. Our previous research using yeast as a model system showed that more than half of the deleterious missense mutations in MSH2 result in lower levels of the protein (9) . The clinical goal of this research was to find small molecules that would restore function and chemosensitivity to mismatch-repair-defective tumors expressing low-level Msh2 variants. Finding a suitable target for drug discovery depended upon identifying the molecular mechanism regulating Msh2 protein levels. The results presented in this work show that unstable Msh2 variant levels are controlled by the ubiquitin/proteasome degradation pathway and that inhibition of this pathway by a clinically approved drug restores the levels, function, and chemosensitivity of unstable Msh2 missense variants, suggesting a viable adjuvant chemotherapeutic approach to treating certain mismatch-repair-defective tumors.
Results
Low-Level Msh2 Variants Are Unstable and Degraded by the Proteasome. Previously, we characterized >50 missense mutations in the mismatch repair gene MSH2 (9) . Half of the defective missense alleles resulted in reduced steady-state levels of Msh2. Of clinical interest, immunohistochemistry showed no detectable protein in the tumor of the equivalent missense variants (SI Appendix and Table 1) , suggesting a strong conservation of regulation from yeast to humans. The substitutions that affect levels correspond to highly conserved amino acids in four clusters on bacterial MutS (9) and human MutSα (SI Appendix and Fig. 1 ). These regions are predicted to influence interdomain interactions and structural integrity, suggesting instability and turnover as the mechanism for the low levels. Furthermore, amino acids important for folding (e.g., proline and glycine) and surface exposure (arginine) are common among the substitutions (9) .
To verify that the low Msh2 levels are a consequence of increased turnover, the rate of degradation for the missense variant proteins with low steady-state levels was assessed and compared with wild-type Msh2. We conducted turnover experiments using the GAL10 inducible/repressible promoter to control expression of each missense variant. The GAL10 promoter allows for repression in glucose medium and strong expression in the presence of galactose. Exponentially growing cells were exposed to galactose for 30 min to express Msh2 and then grown in glucose to repress synthesis. Samples were taken over time after repression and protein immunoblotting experiments were performed (Fig.  1A) . Using these methods, we demonstrated that all low-level variants had shorter half-lives than wild-type Msh2 (Table 1) . We conclude that enhanced turnover of the low-steady-state-level variants is the reason for reduced steady-state levels.
The presence of the higher-molecular-weight species of Msh2 in overexposed blots from these and other assays led us to investigate whether yeast Msh2 is regulated by the ubiquitinationproteasome degradation pathway. First, we expressed a representative low-level variant in a pre1-1 pre2-2 yeast strain expressing temperature-sensitive subunits of the 20S proteasome. A lowlevel variant of Msh2 displayed increased steady-state levels at the nonpermissive temperature (Fig. 1B) . Additionally, the turnover rate of a low-level variant was decreased in the pre1-1 pre2-2 mutant at the semipermissive temperature compared with the rate in a wild-type strain (Fig. 1C) . Second, we conducted turnover experiments in the presence and absence of the MG132 proteasome inhibitor. The MG132 turnover experiments were done by using an erg6Δ strain to increase the permeability of the drug. We found that a low-level variant was stabilized by MG132, but not by PMSF, a vaculolar/lysosomal inhibitor, or DMSO, the solvent used for MG132 (Fig. 1D) .
To establish whether Msh2 is directly ubiquitinated, an Msh2 missense variant was overexpressed to enrich for the transient ubiquitinated species, purified by immunoprecipitation, processed for immunoblotting, and probed with α-ubiquitin (Fig. 1E) . The membrane was stripped and reprobed to detect Msh2. We observed a high-molecular-weight smear of ubiquitinated species, providing evidence for the direct ubiquitination of a low-level Msh2 variant. Together, the data are consistent with the regulation of unstable Msh2 by means of ubiquitination and proteasomal degradation.
Restoring Protein Levels Restores Mismatch Repair for Half of the Low-Level Variants. With the goal of finding a potential chemotherapeutic regime for certain Lynch syndrome tumors, we tested whether increased levels of the missense variants restored mismatch repair in vivo. We restored levels through elevated copy number and exogenous expression. Specifically, we assessed the ability to suppress an msh2 deletion with endogenously expressed or with high-copy, GAL10-induced missense variants. The functional assay used a DNA polymerase mutant strain in which DNA mismatch repair is essential (SI Appendix). In this assay, survival on 5-fluoroorotic acid (5-FOA) indicates a suppression of the mismatch repair defect ( Fig. 2A) . The results show that for the highcopy constructs with the GAL10 promoter driving expression, pregrowth in galactose was required for suppression of the mismatch repair phenotype. As anticipated from our mutation frequency assays (9), we found that the cells with the vector control and the unstable variants expressed from the endogenous MSH2 promoter could not suppress the mismatch repair defect ( Fig. 2A) . In 52% of the cases, we observed that higher expression of the unstable missense allele rescued the mismatch repair defect to a level comparable with wild-type MSH2 ( Fig. 2A and Table 1 ). The restoration of function of more than half of the unstable variants represented an essential first step to proving that the proposed therapeutic approach of rescuing mismatch repair was a feasible approach.
To develop a practical treatment option, it is important to determine how much protein is required to restore mismatch-repair function. One advantage of the GAL10 promoter fusion system is that expression levels are titratable by varying the glucose concentration in the medium. We conducted a titration experiment using a representative missense variant capable of high-copy rescue. Specifically, we used the GAL10-msh2-D524Y fusion in the mismatch repair restoration assay strain described above. The cells were propagated in 2% (wt/vol) galactose, and glucose concentrations were varied from 0 to 2% to express different levels of Msh2 D524Y (Fig. 2B ). Wild-type Msh2 and Msh2 D524Y levels expressed from the endogenous promoter under low-copy conditions were also analyzed for reference. The cells exhibiting growth indicated that sufficient levels of Msh2 D524Y were produced to restore mismatch repair (Fig. 2B ). Mismatch repair restoration was observed even when the Msh2 D524Y protein level was below 
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the wild-type level (Fig. 2C) . Thus, a representative variant does not require overexpression to restore function. Additionally, the levels required are similar to those achieved with genetic and chemical inhibition of the proteasome (Fig. 1) .
San1 Is the Ubiquitin Ligase for the Low-Level Msh2 Variants. Ubiquitin ligases covalently attach ubiquitin moieties to target proteins and therefore represent a specificity component of the ubiquitin/ proteasome pathway (10) . We screened the entire panel of ∼50 viable ubiquitin ligase deletion mutant strains to identify the ligase for Msh2 variants. Because the steady-state level of Msh2 is a good proxy for turnover rates, our strategy included the examination of the levels of a representative Msh2 variant in ubiquitin ligase deletion mutants compared with their level in an isogenic wild-type. Fig. 3A shows the analysis with Msh2 G711D in the deletions of SAN1, PIB1, and DOA10 as well as the isogenic wild type in the presence or absence of overexpressed ubiquitin. Deletion of San1, a nuclear ligase that targets misfolded nuclear proteins (11), stabilized the Msh2 variant and overexpressing ubiquitin partially suppressed the stabilization. Furthermore, turnover experiments confirmed that the elevated steady-state level in a strain lacking San1 was a consequence of decreased turnover (Fig. 3B) .
If San1 is the ubiquitin ligase targeting Msh2, one would expect a decrease in ubiquitination of Msh2 in the absence of San1. To enrich for ubiquitinated Msh2, we overexpressed a representative variant Msh2 A618V in the pre2-2 pre1-1 background with and without San1. Subsequently, we immunoprecipitated Msh2 A618V , prepared the samples for immunoblotting, and probed first for ubiquitin. We then stripped and reprobed to detect Msh2. The ubiquitinated forms of Msh2 A618V reproducibly decreased in the absence of San1 (Fig. 3C) , further supporting the conclusion that San1 targets unstable Msh2 variants.
To determine whether San1 interacts with the unstable Msh2 variants, we took advantage of the yeast two-hybrid assay. We fused the Gal4 activating domain (GAD) to an ubiquitinationdeficient version of San1 that contains the C279S substitution in the RING domain (11) . This construct was coexpressed with the Gal4 DNA binding domain (GBD) fused to the missense variants of Msh2 (9) . The yeast two-hybrid reporter strain contains HIS3 under control of the GAL4 promoter, and the ability of the cells to grow in the absence of histidine indicates a positive interaction between San1 and the Msh2 variants. San1 did not interact with the wild-type version of Msh2, but it interacted with all of the low-level missense variants (e.g., in Fig. 3D and Table  1 ); however, the interaction with the Msh2 R542P variant was significantly less compared with the other variants. Finally, we determined whether all of the low-level variants are stabilized by deleting SAN1 (san1Δ). We established that all but the Msh2 R542P variant were fully stabilized to wild-type levels (e.g., Fig. 3E and Table 1 ).
Because deletion of SAN1(san1Δ) elevated the levels of most of the Msh2 variants back to wild-type levels, the san1Δ background represented an ideal condition for testing whether wild-type levels of the variants allowed for restored mismatch repair. To test whether san1Δ could suppress the low-level Msh2 defects, qualitative and quantitative mismatch-repair assays were performed by using the CAN1 forward mutation assay and the hom3-10 reversion assay. The qualitative results showed that san1Δ conferred the most significant suppression of the mismatch-repair defect for two low-level variants, msh2-D524Y and -A618V (Fig. 3F and Table 1 ). Fluctuation assays were used to quantify the degree of suppression of these two missense alleles (Fig. 3G) . The defects were suppressed to a rate intermediate between the null and wild-type rates. Thus, simply restoring two Msh2 variants to wild-type levels was sufficient to improve mismatch repair.
In summary, San1, an ubiquitin ligase for misfolded nuclear proteins, ubiquitinates unstable variants of Msh2, thereby targeting them for degradation by the proteasome. In the absence of San1 activity, the unstable Msh2 variants are restored to wild-type levels, and in certain cases mismatch repair functionality is improved. The genetic analysis confirmed that function could be restored by elevating the levels of approximately half of the unstable variants; however, to be transferable to the clinic, a small molecule leading to Msh2 stabilization is required. The turnover data presented above suggested that chemically inhibiting the proteasome represents a viable option for elevating the levels of the unstable Msh2 variants. Inhibiting the proteasome is an approved therapeutic regime in the treatment of multiple myeloma and mantle cell lymphomas (www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000358).
Bortezomib is a molecule similar to MG132 in both its chemical structure and mechanism of action. Bortezomib, like MG132, stabilized a low-level variant in a dose-dependent fashion (Fig. 4A) . Additionally, the protein was stabilized at concentrations that did not inhibit growth (Fig. 4B) . Because we use a strain background 
) and a loading control (PGK) are indicated. (C) pre1-1 pre2-2 strain and AGY227, a wild-type (WT) strain harboring pGAL-MSH2-G711D, were grown to early exponential phase at 30°C in galactose-containing medium and shifted to 37°C for 30 min. Glucose (2%) was added to each culture to repress synthesis and harvested at the indicated times. The Msh2 variant (Msh2
G711D
) and a loading control (PGK) are shown. (D) Turnover experiments using an msh2Δ erg6Δ strain (MY11331) expressing GAL10-msh2-R542P were conducted in the presence of 50 μM MG132 (▲) to inhibit the proteasome, 1 mM PMSF to inhibit vacuolar proteases (■), or DMSO, the solvent for MG132 (♦). Time points after repression of synthesis and chemical addition were processed for immunoblotting. The data were normalized for growth and are expressed as a percentage of the zero time point (% Msh2 R542P ). (E) msh2Δ cells from the yeast deletion collection (131-B-1) encoding the vector (VEC), the low-copy centromere-based plasmid expressing msh2-A618V from the endogenous promoter (CEN), or the high-copy (2μ) plasmid expressing msh2-A618V from the GAL10 promoter were grown overnight in selectable medium containing 2% galactose. Protein extracts were immunoprecipitated, processed for immunoblotting, and probed with α-ubiquitin antibody (α-Ubq). The Ig band is indicated. The membrane was stripped and reprobed to detect the Msh2 variant (Msh2   A618V   ) .
where a multidrug transporter (pdr5Δ) and a biosynthetic gene for ergosterol (erg6Δ) have been deleted, we find that the effective concentrations are similar to those used in human cells (0.5-5.0 μM). Interestingly, the restoration of levels was similar to that observed with the strain expressing proteasome temperature-sensitive alleles. Importantly, the levels obtained were within the range required to restore function to Msh2 D524Y in vivo (Fig. 2) . To test whether Bortezomib restored function, we performed fluctuation assays in which the cultures were cultivated in the presence and absence of Bortezomib overnight. We determined that, although Bortezomib did not significantly alter the rates of mutation for the msh2-null and wild-type strains, the chemical did improve mismatch-repair function for the strains expressing the msh2-D524Y and -A618V variants (Fig. 4C) .
Although the restoration of mismatch repair increased the likelihood that the chemotherapeutic regime would work, we tested whether Bortezomib would also render the cells sensitive to cisplatin. First, we conducted growth curves using the msh2-A618V Fig. 2 . Increasing or restoring expression rescues the mismatch-repair defect of unstable Msh2 variants. (A) An msh2Δ pol3-01 strain kept alive by a URA3-based plasmid expressing wild-type MSH2 was transformed with HIS3 encoding plasmids expressing no MSH2 (vector), endogenously expressed wildtype MSH2 (pMSH2), and variants (pMSH2-allele, e.g., D524Y), as well as high-copy, P GAL10 -driven MSH2 (pGAL-MSH2), and variants (pGAL-MSH2-allele). Stains were grown overnight in medium with galactose (GAL) to activate P GAL10 , with glucose (GLC) to repress P GAL10 , or with raffinose (RAF) that neither activates nor represses P GAL10. Selective pressure for the wild-type MSH2 URA3 plasmid was removed to allow for plasmid loss. , were transformed with the P CUP1 -UBI4 plasmid (27) or the vector (LYS2 2μ) to allow for ubiquitin overexpression (Ubq OE) (+) or no overexpression (−), respectively, when treated with 50 μM CuSO 4 for 3 h before harvesting for immunoblotting. Protein extracts were probed to detect Msh2 G711D and a loading control (PGK). The blot was stripped and reprobed with α-ubiquitin (Ubq). (B) A san1Δ strain and the isogenic wild-type (SAN1) expressing Msh2 G350R were induced with 2% galactose for 30 min and repressed with 2% glucose for the times indicated. Msh2 and a loading control (PGK) are indicated. (C) Temperature-sensitive proteasome mutant strains (pre1-1 pre2-2) with wild-type SAN1 (MY11719) or with a deletion of san1, san1Δ (MY12516) were transformed with pGAL-MSH2-A618V. The variant protein was overexpressed for 2 h at 37°C to enrich for ubiquitinated forms of the protein. The immunoprecipitated proteins were processed for immunoblotting and probed with α-ubiquitin antibody (Ubq). The membrane was stripped and reprobed to detect Msh2 ). Diploids were formed and selected for growth (Growth) on medium lacking leucine and tryptophan (−LEU−TRP) and on selective medium also lacking histidine (−LEU−TRP−HIS) for the yeast two-hybrid interaction (Interaction). (E) A strain with a deletion of the SAN1 ubiquitin ligase (−) and the isogenic wild-type strain (+) expressing Msh2 or variants from a centromere-based plasmid were processed for immunoblotting. (F) MY12336, an msh2Δ san1Δ (san1Δ), and MY12064, an msh2Δ with wild-type SAN1 (SAN1), were transformed with the vector (msh2Δ), with pMSH2 (MSH2), and with plasmids to express the msh2 missense substitutions (msh2-D524Y and -A618V are shown). Equally grown patches of cells from the strains were replica-printed to medium with canavanine (CAN) to determine qualitatively the mutation frequency in the CAN1 forward mutation assay. The cells were also transferred to medium lacking methionine (−MET) to select for cells that had undergone a reversion at the hom3-10 polynucleotide run. (G) The mutation rates for the strain described above were conducted by using the CAN1 forward mutation assay and fluctuation assays. The mutation rates and 95% confidence limits (error bars) are shown.
representative strain and the wild-type control over a range of cisplatin concentrations. The msh2-A618V strain demonstrated robust resistance to cisplatin in the growth curve analysis with significantly faster growth rates and a higher saturation point across the series of concentrations compared with wild type (Fig.  4D) . The msh2-A618V strain demonstrated significantly faster doubling times compared with wild type in a range of cisplatin concentrations (SI Appendix).
We conducted growth curves using the msh2-A618V representative strain and the wild-type control over a range of cisplatin concentrations in the presence and absence of Bortezomib. Experimental and technical replicates showed that Bortezomib caused the msh2-A618V cells to lose the cisplatin-resistance phenotype, resulting in the same growth inhibition as wild-type cells (for an example at 400 μM, see Fig. 4D ). In summary, Bortezomib restored mismatch repair and chemosensitivity in cells expressing an unstable form of Msh2.
Discussion
Our research exploits a model organism to characterize a large panel of human MSH2 missense variants and to translate the molecular finding back to humans. Here, we demonstrate that clinically identified low-level variants of Msh2 are turned over more rapidly than wild-type Msh2 and that the mechanism of degradation is the ubiquitin-proteasome pathway. Elevating levels fully restores functioning for half of the low-level variants. For two of the variants, simply restoring the levels to wild type allowed for full mismatch repair function. Blocking degradation either by deletion of the ubiquitin ligase or through chemical inhibition of the proteasome restored levels and function to two variants. Of clinical significance, our finding that a clinically approved proteasome inhibitor restores sensitivity to cisplatin in cells expressing an Msh2 missense variant suggests a viable adjuvant chemotherapeutic approach to treating certain mismatchrepair-defective tumors.
Using Model Organisms to Characterize Single-Nucleotide Polymorphisms in Humans and Develop Personalized Medicine Approaches. Whole-genome sequencing has uncovered an immense quantity of data, including the variation found in the human genome (12) . A significant task going forward is functionally characterizing singlenucleotide polymorphisms (SNPs) in the human population. We advocate taking an approach similar to the one we have taken to characterize the clinically identified SNPs in the MSH2 coding region. Given the conservation of genes from fungi to humans combined with the state-of-the-art genomic approaches available to fungal researchers, rapid and significant progress could be made characterizing SNPs of unknown function.
This research represents how characterizing clinically significant human variants in a genetically defined model organism can be used to devise personalized approaches to treating cancer. The Msh2 missense variants shown in this work to respond to the effects of Bortezomib treatment were first identified in cancer patients. The Msh2 D506Y variant was found in a Korean individual with early onset rectal cancer; however, no other information about the cancer phenotype was reported (13) . The Msh2 A600V variant, originally identified in a 35-y-old Japanese male with rectal cancer (14) , was also found in his mother, who suffered endometrial, ovarian, and , and pdr5Δ erg6Δ were tested for sensitivity to Bortezomib. Approximately 10 4 cells were plated, and filter discs were placed on the plates. Bortezomib (in DMSO) or DMSO was applied to the disk at the indicated concentrations. (C) MY12078 (pdr5Δ erg6Δ msh2Δ) was transformed with centromere-based plasmids expressing no MSH2 (msh2Δ), msh2-D524Y, msh2-A618V, or wild-type MSH2. Cultures were grown in the absence (DMSO) or presence of 5 μM Bortezomib in DMSO overnight and processed to calculate the CAN1 forward mutation rate as described in Materials and Methods. Error bars indicate 95% confidence limits. (D) msh2-A618V or wildtype MSH2 cultures from above were grown in a range of cisplatin concentrations (400 μM shown) in the absence or presence of 1 μM Bortezomib overnight in a microtiter dish, and the optical density at 600 nm was detected every 15 min for 48 h.
colon cancer (15) . Tumors from both individuals displayed significant microsatellite instability, and Msh2 was not detectable by immunohistochemistry. These clinical findings correlate with the mismatch-repair defect and unstable phenotype that we observed in yeast.
The significant stabilization and restoration of function caused by deleting the San1 ligase underscores the value of searching for a drug that would specifically target the ubiquitin ligase responsible for the turnover of unstable forms of Msh2. Although there is not an obvious homolog of San1 based on sequence homology, there is undoubtedly a human ubiquitin ligase responsible for targeting misfolded nuclear proteins. Until a more specific target is identified, we predict that Bortezomib will restore protein levels and mismatch-repair functioning in certain tumors, thereby changing the cells from chemoresistant to chemosensitive. The conservation of structure, function, and regulation (this work and ref. 16) of MutS from yeast to humans suggests that this therapeutic approach is feasible. Examples of our proposed strategy are found where chemically restoring the Mlh1 mismatch-repair protein levels caused by promoter hypermethylation resulted in regained sensitivity to chemotherapeutic agents (17) .
Other Clinically Significant Missense Variants May also Be Rescued by
Bortezomib. The pathology of ubiquitin-mediated turnover of missense variants of Msh2 is in keeping with mounting evidence that other human diseases, such as cystic fibrosis and Huntington, Alzheimer's, and Parkinson diseases are linked to proteinfolding abnormalities resulting in instability and ubiquitin-positive aggregates (18, 19) . Interestingly, diseases including neurofibromatosis (20) , multiple endocrine neoplasia Type 1 (21), α-1 antitrypsin deficiency (22) , classic late-infantile neuronal ceroid lipofuscinosis (23) , and phenylketonuria (24) all have incidences in which missense variants are targeted by the ubiquitin-proteasome pathway. Thus, small-molecule stabilization of missense variants or the targeted inhibition of the ubiquitin pathway represent exciting avenues for therapeutic exploration for many diseases, not just Lynch syndrome.
Materials and Methods
Strains, Plasmids, and Reagents. Strains and plasmids are listed in the SI Appendix, Tables S3 and S4, respectively. Microbial and molecular techniques were described (9) . Bortezomib was from Selleck Chemicals. DMSO, MG13,2 and PMSF were from Sigma Aldrich. The 12CA5 α-HA (Santa Cruz Biotechnology), α-mouse IgG-HRP (GE Healthcare Life Sciences), α-PGK (Sigma Aldrich), and P4D1 α-ubiquitin (Covance) antibodies were used at the recommended dilutions.
Protein Turnover and Ubiquitin Assays. Immunoblotting analysis was conducted as described (9) . Turnover assays are described in detail in SI Appendix. The ubiquitin immunoprecipitation assay (25) used a cell lysis in the presence of N-ethylmaleimide (Sigma Aldrich) and dissolved protease inhibitor mixture tablets (Roche Applied Science). Msh2 was immunoprecipitated by using α-HA-agarose beads (clone HA-7; Sigma Aldrich).
Mismatch-Repair Assays. The mismatch-repair assays in the pol3-01 strain background are described in detail in SI Appendix. Qualitative mismatchrepair assays were as described (9) . The hom3-10 reversion assay was selected for using synthetic medium lacking methionine. Fluctuation assays were used to determine the rates at which cells mutated to become resistant to canavanine as described (26) . Mutation rates were calculated by using both the P 0 and maximum-likelihood methods.
Growth Curves and Cisplatin Resistance. MY12078 (pdr5Δ erg6Δ msh2Δ) was transformed with centromere-based plasmids expressing msh2-A618V or wildtype MSH2. Overnight cultures were diluted into fresh medium in a microtiter dish with a range of cisplatin (Sigma Aldrich) concentrations (0-500 μM) in the absence or presence of 1 μM Bortezomib. The cultures were grown overnight at 30°C with continuous agitation, and the optical density at 600 nm was detected every 15 min for 48 h by using a BioTek Synergy H1 Microplate Reader.
